Press releases

December

• 12/21/16 - Bone Therapeutics announces its financial calendar for 2017

November

• 11/8/16 - Bone Therapeutics Business Update for Third Quarter 2016
• 11/2/16 - Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016

October

• 10/11/16 - Enrico Bastianelli to stand down as CEO of Bone Therapeutics
• 10/11/16 - Transparency notification received from Theodorus II SA
• 10/5/16 - Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial

September

• 9/15/16 - Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

August

• 8/30/16 - Bone Therapeutics announces H1 results for 2016
• 8/25/16 - Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016

June

• 6/8/16 - Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
• 6/3/16 - Bone Therapeutics celebrates ten years of innovation in bone cell therapy

May

• 5/19/16 - Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
• 5/17/16 - Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
• 5/10/16 - Bone Therapeutics Provides Business Update for the First Quarter of 2016
• 5/3/16 - Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study

April

• 4/26/16 - The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available
• 4/14/16 - Bone Therapeutics announces the publication of its Annual Report 2015

March

• 3/29/16 - Bone Therapeutics Reports Full Year 2015 Results
• 3/29/16 - Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
• 3/16/16 - Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016

February

• 2/24/16 - Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference
• 2/17/16 - Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015
• 2/17/16 - Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
• 2/2/16 - Bone Therapeutics extends Kasios collaboration

January

• 1/20/16 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016
• 1/18/16 - Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures
• 1/13/16 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016
• 1/5/16 - Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region

December

• 12/23/15 - Bone Therapeutics announces its financial calendar for 2016
• 12/15/15 - Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial
• 12/11/15 - ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference

November

• 11/30/15 - Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
• 11/18/15 - Bone Therapeutics Provides Business Update for the Third Quarter of 2015
• 11/12/15 - Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA
• 11/9/15 - Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

October

• 10/22/15 - Transparency notification received from S.R.I.W. SA & Sofipôle SA
• 10/13/15 - Bone Therapeutics to participate in key investor conferences in Q4 2015

September

• 9/28/15 - Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion
• 9/22/15 - Bone Therapeutics announces half-year results for 2015
• 9/21/15 - Bone Therapeutics Notice of Half Year Results 2015
• 9/7/15 - Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial

June

• 6/22/15 - Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis

May

• 5/15/15 - Bone Therapeutics Provides Business Update for the First Quarter 2015

April

• 4/28/15 - Bone Therapeutics Reports 2014 Financial and Operational Results
• 4/24/15 - Bone Therapeutics officially opens its new headquarters in Gosselies
• 4/13/15 - Bone Therapeutics Establishes US Subsidiary

March

• 3/23/15 - Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial
• 3/2/15 - Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial

February

• 2/19/15 - Information on the total number of voting rights and shares
• 2/18/15 - Bone Therapeutics announces its financial calendar for 2015
• 2/17/15 - Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA
• 2/16/15 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015
• 2/11/15 - Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
• 2/4/15 - Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

January

• 1/21/15 - Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris
• 1/19/15 - Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
• 1/16/15 - Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
• 1/5/15 - Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

December

• 12/4/14 - Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®

November

• ALLOBIF Collaboration
• 11/17/14 - Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures

October

• Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany

September

• Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
• Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)

July

• Bone Therapeutics and Partners awarded over €0.5 million M-ERA.net research funding to develop 3-D patient-tailored bone tissue engineered products

June

• Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product

January

• Bone Therapeutics to present at Biotech Showcase in San Francisco on Tuesday 14 January, 2014 at 10.15am

December

• Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant

November

• Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active
• Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures

October

• Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial

September

• Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer

June

• Establishment of the Walloon Cell Therapy Platform: The platform aims to produce cell therapy medicines on a large scale
• Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle

April

• Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®
• Bone Therapeutics to Present at Upcoming Investor Conferences

March

• Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products

February

• Bone Therapeutics Invests in Cell Therapy Manufacturing Facility

January

• Bone Therapeutics Raises €7.7 Million in Series D Fundraising

October

• Bone Therapeutics receives clearance for its pivotal phase III osteonecrosis trial with PREOB® in Europe and treats the first patients in the study
• Bone Therapeutics reçoit l'approbation des autorités et traite les premiers patients dans son étude clinique de phase III en ostéonécrose avec son produit PREOB®

February

• Bone Therapeutics lève 9,5M €

June

• Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel